vTv Therapeutics (NASDAQ:VTVT) has been assigned a $15.00 target price by equities research analysts at Canaccord Genuity in a report released on Thursday, December 21st. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 170.76% from the stock’s current price.
A number of other equities analysts have also recently commented on the company. Citigroup reiterated an “add” rating on shares of vTv Therapeutics in a report on Wednesday, November 8th. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 target price on shares of vTv Therapeutics in a report on Friday, November 3rd. Finally, Zacks Investment Research cut vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.10.
vTv Therapeutics (NASDAQ:VTVT) opened at $5.54 on Thursday. vTv Therapeutics has a 1-year low of $3.57 and a 1-year high of $8.09.
In other news, major shareholder Ronald O. Perelman bought 50,000 shares of the firm’s stock in a transaction on Tuesday, December 26th. The stock was acquired at an average cost of $4.03 per share, with a total value of $201,500.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Paul G. Savas bought 15,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were purchased at an average cost of $4.56 per share, with a total value of $68,400.00. Following the completion of the transaction, the director now owns 81,781 shares in the company, valued at $372,921.36. The disclosure for this purchase can be found here. 0.80% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics in the 3rd quarter valued at $481,000. State Street Corp increased its holdings in shares of vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of vTv Therapeutics by 62.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after acquiring an additional 101,850 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of vTv Therapeutics by 4.8% in the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 2,900 shares during the period. 10.42% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/14/vtv-therapeutics-vtvt-given-a-15-00-price-target-by-canaccord-genuity-analysts-2-updated-updated-updated.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.